(NASDAQ: IOVA) Iovance Biotherapeutics's forecast annual revenue growth rate of 120.31% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.33%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.84%.
Iovance Biotherapeutics's revenue in 2025 is $90,858,000.On average, 7 Wall Street analysts forecast IOVA's revenue for 2025 to be $137,148,917,254, with the lowest IOVA revenue forecast at $122,933,331,647, and the highest IOVA revenue forecast at $143,033,624,747. On average, 6 Wall Street analysts forecast IOVA's revenue for 2026 to be $229,142,731,784, with the lowest IOVA revenue forecast at $149,577,268,308, and the highest IOVA revenue forecast at $309,962,063,430.
In 2027, IOVA is forecast to generate $288,369,868,362 in revenue, with the lowest revenue forecast at $226,866,628,844 and the highest revenue forecast at $367,827,744,219.